News Novo Nordisk rises as Hims & Hers backs down on oral GLP-1 Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.
News Leqembi starts to deliver for Eisai and Biogen Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.
News White House's TrumpRx platform has arrived The Trump administration's long-promised direct-to-consumer (DTC) sales channel for medicines, TrumpRx, has finally gone live.
News Hims & Hers copies Novo Nordisk's new Wegovy pill Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version.
News Amgen baulks at FDA request to withdraw Tavneos Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated vasculitis from the US market.
News Grail multi-cancer test taps into Hims & Hers network Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.
News Trial miss doesn't dent Biogen's faith in Alzheimer's drug Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.